Oslo, Norway, 8 March 2024: Reference is made to the stock exchange announcement
published by Circio Holding ASA (the "Company") on 28 September 2023 regarding
the approval of a registration document (the "Registration Document") which was
prepared to be used as a base prospectus for the purpose of listing new shares
in the Company related to the convertible bond facility with Atlas Special
Opportunities LLC ("Atlas").

Further reference is made to the stock exchange announcements published by the
Company on 4 and 5 March 2024, announcing that Atlas had by notice of
conversion, requested conversion of convertible bonds into a total of 171,154
new shares in the Company. A total of 99,548 of the new shares (the "New
Shares") were issued at a separate ISIN pending publication of a prospectus.

The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today
approved a securities note, a supplement to the Registration Document and a
summary (together with the Registration Document, referred to as the
"Prospectus") prepared for the listing of the New Shares.

The Prospectus is available at the Company's website
https://www.circio.com/en/section/investors/prospectus/.

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for rare disease, vaccines, and cancer. The proprietary
circVec technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA from DNA and viral vectors, which can be
deployed for many purposes. The circVec platform has demonstrated enhanced and
more durable protein expression than classic mRNA vector systems, and has the
potential to become the new gold-standard for DNA and virus-based therapeutics
in the future. The circRNA R&D activities are being conducted by the wholly
owned subsidiary Circio AB based at the Karolinska Institute in Stockholm,
Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in three clinical trials: RAS-mutated
pancreatic cancer and lung and non-resectable pancreatic cancer in US, and
multiple myeloma in Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating read-outs and future
optionality for the program at low cost to Circio.